Rosiglitazone reduces tau phosphorylation via JNK inhibition in the hippocampus of rats with type 2 diabetes and tau transfected SH-SY5Y cells

Neurobiology of Disease

Volumn 40, Issue 2, 2010, Pages 449-455

  Yoon, Seung Yong ^a   Park, Jeong Su ^a   Choi, Jung Eun ^a   Choi, Jin Myung ^a   Lee, Woo Je ^a   Kim, Seong Who ^a   Kim, Dong Hou ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Alzheimer's disease; Diabetes; PPAR ; Rosiglitazone; Tau phosphorylation

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; ROSIGLITAZONE; STREPTOZOCIN; STRESS ACTIVATED PROTEIN KINASE; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC TRANSFECTION; HIPPOCAMPUS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NEUROBLASTOMA CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL LINE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GLYCOGEN SYNTHASE KINASE 3; HIPPOCAMPUS; HUMANS; HYPOGLYCEMIC AGENTS; INFANT; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; MICE, INBRED C57BL; NEURONS; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; PPAR GAMMA; RATS; RATS, INBRED OLETF; TAU PROTEINS; THIAZOLIDINEDIONES; TRANSFECTION; TREATMENT OUTCOME;

EID: 77956611181     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.07.005     Document Type: Article

References (45)

1. Arriagada P.V., et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992, 42:631-639.
2. Bryant J.C., et al. Methylated C-terminal leucine residue of PP2A catalytic subunit is important for binding of regulatory Balpha subunit. Biochem. J. 1999, 339(Pt 2):241-246.
3. Chen J., et al. Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. Science 1992, 257:1261-1264.
4. Clodfelder-Miller B.J., et al. Tau is hyperphosphorylated at multiple sites in mouse brain in vivo after streptozotocin-induced insulin deficiency. Diabetes 2006, 55:3320-3325.
5. Cole G.M., Frautschy S.A. The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's disease. Exp. Gerontol. 2006, 42:10-21.
6. De Felice F.G., et al. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol. Aging 2008, 29:1334-1347.
7. De Felice F.G., et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:1971-1976.
8. Dhanasekaran D.N., Reddy E.P. JNK signaling in apoptosis. Oncogene 2008, 27:6245-6251.
9. Escribano L., et al. Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 2010, 35:1593-1604.
10. Feinstein D.L., et al. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?. Biochem. Pharmacol. 2005, 70:177-188.
11. Ferrer I., et al. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol. 2002, 104:583-591.
12. Gomez-Isla T., et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 1997, 41:17-24.
13. Grundke-Iqbal I., et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:4913-4917.
14. Ivaska J., et al. Integrin alpha 2 beta 1 promotes activation of protein phosphatase 2A and dephosphorylation of Akt and glycogen synthase kinase 3 beta. Mol. Cell. Biol. 2002, 22:1352-1359.
15. Janson J., et al. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004, 53:474-481.
16. Khandoudi N., et al. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 2002, 51:1507-1514.
17. Kodl C.T., Seaquist E.R. Cognitive dysfunction and diabetes mellitus. Endocr. Rev. 2008, 29:494-511.
18. Koh E.H., et al. Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation. Diabetes 2003, 52:2331-2337.
19. Landreth G., et al. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 2008, 5:481-489.
20. Lee C.S., et al. New mechanism of rosiglitazone to reduce neointimal hyperplasia: activation of glycogen synthase kinase-3beta followed by inhibition of MMP-9. Arterioscler. Thromb. Vasc. Biol. 2009, 29:472-479.
21. Li Z.G., et al. Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 2007, 56:1817-1824.
22. Lim Y.W., et al. Maintained activity of glycogen synthase kinase-3β despite of its phosphorylation at serine-9 in okadaic acid-induced neurodegenerative model. Biochem. Biophys. Res. Commun. 2010, 395:207-212.
23. Liu F., et al. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:10804-10809.
24. Liu Y., et al. Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease. J. Neurochem. 2009, 111:242-249.
25. Ma Q.L., et al. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J. Neurosci. 2009, 29:9078-9089.
26. Mackay E.A., et al. A possible role for cathepsins D, E, and B in the processing of beta-amyloid precursor protein in Alzheimer's disease. Eur. J. Biochem. 1997, 244:414-425.
27. Moloney A.M., et al. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging 2010, 31:224-243.
28. Mora A., et al. Lithium blocks the PKB and GSK3 dephosphorylation induced by ceramide through protein phosphatase-2A. Cell. Signal. 2002, 14:557-562.
29. Park S., et al. The inhibition of insulin-stimulated proliferation of vascular smooth muscle cells by rosiglitazone is mediated by the Akt-mTOR-P70S6K pathway. Yonsei Med. J. 2008, 49:592-600.
30. Perlmuter L.C., et al. Decreased cognitive function in aging non-insulin-dependent diabetic patients. Am. J. Med. 1984, 77:1043-1048.
31. Planel E., et al. Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J. Neurosci. 2007, 27:13635-13648.
32. Schubert M., et al. Role for neuronal insulin resistance in neurodegenerative diseases. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:3100-3105.
33. Shoji M., et al. JNK activation is associated with intracellular beta-amyloid accumulation. Brain Res. Mol. Brain Res. 2000, 85:221-233.
34. Song M.S., et al. Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation. Eur. J. Neurosci. 2008, 28:1989-2002.
35. Sontag E., et al. Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies. J. Biol. Chem. 1999, 274:25490-25498.
36. Steinhilb M.L., et al. S/P and T/P phosphorylation is critical for tau neurotoxicity in Drosophila. J. Neurosci. Res. 2007, 85:1271-1278.
37. Stranahan A.M., et al. Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nat. Neurosci. 2008, 11:309-317.
38. Swatton J.E., et al. Increased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain. Eur. J. Neurosci. 2004, 19:2711-2719.
39. Taghibiglou C., et al. Mechanisms involved in cholesterol-induced neuronal insulin resistance. Neuropharmacology 2009, 57:268-276.
40. Yoon S.Y., et al. Construction of a vector generating both siRNA and a fluorescent reporter: a siRNA study in cultured neurons. Mol. Cells 2004, 18:127-130.
41. Yoon S.Y., et al. Inactivation of GSK-3beta in okadaic acid-induced neurodegeneration: relevance to Alzheimer's disease. Neuroreport 2005, 16:223-227.
42. Yue T.L., et al. Rosiglitazone treatment in Zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes 2005, 54:554-562.
43. Zhao W.Q., Townsend M. Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim. Biophys. Acta 2009, 1792:482-496.
44. Zhao W.Q., et al. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J. 2008, 22:246-260.
45. Zhu X., et al. Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J. Neurochem. 2001, 76:435-441.